Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Decline in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 14,800 shares, a decline of 50.3% from the July 15th total of 29,800 shares. Based on an average trading volume of 22,900 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.0% of the company’s shares are sold short.

Barinthus Biotherapeutics Trading Down 0.4 %

Barinthus Biotherapeutics stock traded down $0.00 during trading hours on Wednesday, hitting $1.32. 4,365 shares of the stock traded hands, compared to its average volume of 20,976. Barinthus Biotherapeutics has a one year low of $1.21 and a one year high of $5.10. The company has a market cap of $51.52 million, a PE ratio of -0.75 and a beta of -0.52. The firm’s 50-day moving average price is $1.51 and its two-hundred day moving average price is $2.18.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, sell-side analysts expect that Barinthus Biotherapeutics will post -1.9 earnings per share for the current fiscal year.

Institutional Trading of Barinthus Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. M&G Plc purchased a new position in Barinthus Biotherapeutics during the 2nd quarter valued at about $7,276,000. Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics during the second quarter valued at approximately $2,119,000. Catalina Capital Group LLC purchased a new position in shares of Barinthus Biotherapeutics during the second quarter valued at approximately $25,000. Ipswich Investment Management Co. Inc. bought a new stake in shares of Barinthus Biotherapeutics in the 2nd quarter worth approximately $32,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Barinthus Biotherapeutics in the 1st quarter worth approximately $1,292,000. 25.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BRNS. Barclays dropped their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating for the company in a report on Thursday, June 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Barinthus Biotherapeutics in a research report on Monday. William Blair restated an “outperform” rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th. Finally, Alliance Global Partners cut their price target on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a report on Tuesday.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.